| Literature DB >> 25530886 |
Juliana Rodrigues Tovar1, Eliana Zandonade2, Maria Helena Costa Amorim2.
Abstract
Conservative surgery is considered the procedure of choice for women who are affected by early stage tumours. The local recurrence of cancer as a consequence of breast tissue conservation is a growing concern. This study aimed to describe the sociodemographic and clinical profiles of women who had local recurrences of breast cancer after conservative surgery and to examine the associations between sociodemographic and clinical variables and the incidence of tumour recurrence in these women. The retrospective cohort included 880 women who were diagnosed with breast cancer and underwent conservative surgery between January 2000 and December 2010. Recurrences occurred in 60 patients, and the mean age of the women at diagnosis was 48.8 years. Predictive factors for local recurrence were young age (<39 years) (P = 0.028 and OR = 10.93), surgical margin involvement (P = 0.001 and OR = 3.66), and Her-2 overexpression (P = 0.045 and OR = 1.94). The establishment of sociodemographic and clinical characteristics might help to select optimum treatments, which is a crucial challenge for public health in Brazil, especially with regard to reductions of surgery and hospitalisation expenditures in the Unified Health System (Sistema Único de Saúde-SUS).Entities:
Year: 2014 PMID: 25530886 PMCID: PMC4235109 DOI: 10.1155/2014/639534
Source DB: PubMed Journal: Int J Breast Cancer ISSN: 2090-3189
Sociodemographic and clinical characterisation of women with recurrent breast cancer who underwent breast-conserving surgery and were enrolled in the HSRC during the period from January 1, 2000 to December 31, 2010.
| Variable | Category |
| % |
|---|---|---|---|
| Age group | 30 to 39 years |
|
|
| 40 to 49 years |
|
| |
| 50 to 59 years | 16 | 27% | |
| 60 to 69 years | 9 | 15% | |
| 80 or more | 1 | 2% | |
|
| |||
| Race/ethnicity | White | 14 | 23% |
| Nonwhite |
|
| |
|
| |||
| Location of primary tumour | Nipple | 2 | 5% |
| Upper inner quadrant | 8 | 21% | |
| Lower inner quadrant | 5 | 13% | |
| Upper outer quadrant |
|
| |
| Lower outer quadrant | 1 | 3% | |
|
| |||
| Histological type | Others | 1 | 2% |
| Ductal and mixed carcinoma |
|
| |
| Lobular carcinoma | 5 | 8% | |
|
| |||
| Stage | Initial |
|
|
| Late | 4 | 7% | |
|
| |||
| First postsurgery treatment | RT | 22 | 36.7% |
| CT |
|
| |
| Hormone | 2 | 3.3% | |
| None | 0 | 0% | |
|
| |||
| Laterality | Right |
|
|
| Left | 28 | 47% | |
|
| |||
| Size in cm | 0.5 or less | 3 | 5% |
| 0.6 to 1.0 | 6 | 10% | |
| 1.1 to 1.5 | 5 | 8% | |
| 1.6 to 2.0 | 16 | 27% | |
| >2.0 |
|
| |
|
| |||
| Vascular and/or lymph invasion | No |
|
|
| Yes | 14 | 24% | |
|
| |||
| Surgical margin involvement | Negative |
|
|
| Positive | 12 | 20% | |
|
| |||
| Number of axillary lymph nodes involved | 0 |
|
|
| 1–3 | 12 | 21% | |
| >3 | 5 | 9% | |
|
| |||
| Sentinel lymph node detection technique | Dye |
|
|
| Radiopharmaceutical | 2 | 8% | |
| Both | 1 | 4% | |
|
| |||
| Estrogen receptor | Negative | 17 | 29% |
| Positive |
|
| |
|
| |||
| Progesterone receptor | Negative | 18 | 31% |
| Positive |
|
| |
|
| |||
| Her-2 | Negative |
|
|
| Positive | 19 | 35% | |
|
| |||
| p53 | Negative |
|
|
| Positive | 14 | 31% | |
RT: radiotherapy, CT: chemotherapy.
Relationships between sociodemographic and clinical variables and the incidence of breast cancer recurrence in women who underwent breast-conserving surgery and were registered in HSRC during the period from January 1, 2000 to December 31, 2010.
| Variable | Category | Recurrence |
| |||
|---|---|---|---|---|---|---|
| No | Yes | |||||
|
| % |
| % | |||
| Age group | Less than 39 years |
|
|
|
|
|
| 40 to 49 years | 230 | 28% | 21 | 35% | ||
| 50 to 59 years | 240 | 29% | 16 | 27% | ||
| 60 to 69 years | 174 | 21% | 9 | 15% | ||
| 70 years or more | 100 | 12% | 1 | 2% | ||
|
| ||||||
| Race/ethnicity | White | 278 | 34% | 14 | 23% | 0.086 |
| Nonwhite | 536 | 66% | 46 | 77% | ||
|
| ||||||
| Location of primary tumour | Nipple | 22 | 4% | 2 | 5% | 0.539 |
| Upper inner quadrant | 61 | 12% | 8 | 21% | ||
| Lower inner quadrant | 56 | 11% | 5 | 13% | ||
| Upper outer quadrant | 324 | 66% | 22 | 58% | ||
| Lower outer quadrant | 28 | 6% | 1 | 3% | ||
|
| ||||||
| Histological type | Ductal and mixed carcinoma | 703 | 86% | 54 | 90% | 0.075 |
| Lobular carcinoma | 40 | 5% | 5 | 8% | ||
| Others | 77 | 9% | 1 | 2% | ||
|
| ||||||
| Stage | Initial | 611 | 95% | 56 | 93% | 0.570 |
| Late | 32 | 5% | 4 | 7% | ||
|
| ||||||
| First postsurgery treatment | None | 42 | 5% | 0 | 0% |
|
| RT | 388 | 47% | 22 | 37% | ||
| CT |
|
|
|
| ||
| Hormone | 45 | 5% | 2 | 3% | ||
|
| ||||||
| Laterality | Right | 408 | 51% | 32 | 53% | 0.678 |
| Left | 399 | 49% | 28 | 47% | ||
|
| ||||||
| Size in cm | 0.5 or less | 60 | 8% | 3 | 5% |
|
| 0.6 to 1.0 | 149 | 19% | 6 | 10% | ||
| 1.1 to 1.5 | 181 | 23% | 5 | 8% | ||
| 1.6 to 2.0 | 152 | 19% | 16 | 27% | ||
| >2.0 |
|
|
|
| ||
|
| ||||||
| Vascular and/or lymph invasion | No | 678 | 85% | 45 | 76% | 0.095 |
| Yes | 124 | 15% | 14 | 24% | ||
|
| ||||||
| Surgical margin involvement | Negative | 752 | 93% | 48 | 80% |
|
| Positive |
|
|
|
| ||
|
| ||||||
| Lymph node involvement | 0 | 555 | 75% | 39 | 70% | 0.672 |
| 1–3 | 126 | 17% | 12 | 21% | ||
| >3 | 63 | 8% | 5 | 9% | ||
|
| ||||||
| Sentinel lymph node detection technique | Dye | 433 | 90% | 23 | 88% | 0.913 |
| Radiopharmaceutical | 28 | 6% | 2 | 8% | ||
| Both | 22 | 5% | 1 | 4% | ||
|
| ||||||
| Oestrogen receptor | Negative | 141 | 20% | 17 | 29% | 0.088 |
| Positive | 568 | 80% | 41 | 71% | ||
|
| ||||||
| Progesterone receptor | Negative | 173 | 25% | 18 | 31% | 0.270 |
| Positive | 533 | 75% | 40 | 69% | ||
|
| ||||||
| Her-2 | Negative | 517 | 79% | 35 | 65% |
|
| Positive |
|
|
|
| ||
|
| ||||||
| p53 | Negative | 345 | 79% | 31 | 69% | 0.129 |
| Positive | 93 | 21% | 14 | 31% | ||
RT: radiotherapy, CT: chemotherapy.
Crude and adjusted odds ratios for statistically significant variables in women with breast cancer who underwent breast-conserving surgery and who were registered in HSRC during the period from January 1, 2000 to December 31, 2010.
| Variables | Categories | Crude OR | Adjusted OR* | ||||||
|---|---|---|---|---|---|---|---|---|---|
|
| OR | LI 95% | LS 95% |
| OR | LI 95% | LS 95% | ||
| Age group | Less than 39 years |
|
|
|
|
|
|
|
|
| 40 to 49 | 0.032 | 9.13 | 1.21 | 68.81 | 0.083 | 6.28 | 0.78 | 50.23 | |
| 50 to 59 | 0.068 | 6.67 | 0.87 | 50.95 | 0.118 | 5.33 | 0.65 | 43.49 | |
| 60 to 69 | 0.122 | 5.17 | 0.65 | 41.43 | 0.147 | 4.89 | 0.57 | 41.86 | |
| 70 years and over | 1.00 | 1.00 | |||||||
|
| |||||||||
| Race/ethnicity | White | 1.00 | 1.00 | ||||||
| Nonwhite | 0.090 | 1.70 | 0.92 | 3.15 | 0.488 | 1.29 | 0.63 | 2.64 | |
|
| |||||||||
| Histological type | Ductal and mixed carcinoma | 0.080 | 5.91 | 0.81 | 43.35 | 0.997 | 1.50 | 0.10 | 4.00 |
| Lobular carcinoma | 0.042 | 9.62 | 1.09 | 85.21 | 0.997 | 1.30 | 0.20 | 3.50 | |
| Others | 1.00 | 1.00 | |||||||
|
| |||||||||
| First treatment after surgery | None | 0.998 | ∗∗ | ∗∗ | ∗∗ | 0.998 | ∗∗ | ∗∗ | ∗∗ |
| RT | 0.747 | 1.28 | 0.29 | 5.60 | 0.886 | 0.89 | 0.18 | 4.40 | |
| CT | 0.251 | 2.35 | 0.55 | 10.08 | 0.789 | 0.80 | 0.16 | 4.05 | |
| Hormone | 1.00 | 1.00 | |||||||
|
| |||||||||
| Size in cm | ≤0.5 | 1.00 | 1.00 | ||||||
| 0.6–1.0 | 0.765 | 0.81 | 0.20 | 3.33 | 0.413 | 0.52 | 0.11 | 2.47 | |
| 1.1–1.5 | 0.426 | 0.55 | 0.13 | 2.38 | 0.257 | 0.41 | 0.09 | 1.93 | |
| 1.6–2.0 | 0.250 | 2.11 | 0.59 | 7.49 | 0.866 | 1.13 | 0.27 | 4.67 | |
| >2.0 | 0.192 | 2.26 | 0.67 | 7.66 | 0.673 | 1.34 | 0.34 | 5.27 | |
|
| |||||||||
| Vascular and/or lymphatic invasion | No | 1.00 | 1.00 | ||||||
| Yes | 0.098 | 1.70 | 0.91 | 3.19 | 0.606 | 1.22 | 0.58 | 2.57 | |
|
| |||||||||
| Surgical margin involvement | Negative | 1.00 | 1.00 | ||||||
| Positive |
|
|
|
|
|
|
|
| |
|
| |||||||||
| Oestrogen receptor | Negative | 1.00 | 1.00 | ||||||
| Positive | 0.091 | 0.60 | 0.33 | 1.09 | 0.101 | 0.56 | 0.29 | 1.12 | |
|
| |||||||||
| Her-2 | Negative | 1.00 | 1.00 | ||||||
| Positive |
|
|
|
|
|
|
|
| |
*The total data analysed were based on 676 women (76.8%), due to missing data in at least one variable.
**could not be calculated because no women with local recurrences remained in this analysis category.
RT: radiotherapy, CT: chemotherapy.